AXL overexpression in NSCLC and several other solid and hematologic cancers drives a wide range of pathophysiological processes, including epithelial to mesenchymal transition, tumor angiogenesis, decreased antitumor immune response, stem cell maintenance, and resistance to targeted and chemotherapeutic agents.6, 7, 8, 9, 10. Here, AXL is linked to neoplasm.